AiCure

While millions of people around the world are prescribed life-saving medications, these medications are effective only when taken correctly. Until now, the gold standard for confirming adherence was to have a care provider directly observe patients taking their medication, otherwise known as directly observed therapy (DOT). Unfortunately, traditional DOT is costly, resource-intensive, intrusive, and disruptive to both health care systems and patients.

AiCure is an NIH-funded artificial intelligence company that has developed advanced facial recognition and motion-sensing software to automate the process of DOT. The patented software, which can be downloaded as an app by patients onto their smartphone or tablet and deployed as a software as a service (SaaS), uses the webcam to visually and automatically confirm that the right patient is taking the right medication at the right time. No human supervision is necessary. Automated DOT® takes just a few seconds to use, adapts to different patient behaviors, cognitive skills and language requirements, and interactively walks the patient through the correct self-administration of oral, inhalable, injectable, and sublingual medications.

AiCure’s platform has the potential to transform the lives of high-risk patient populations around the world and to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment effectiveness and reducing risk. AiCure is also transforming the way clinical research is performed today, helping to ensure that future drugs will have been properly tested for safety and efficacy through the accurate monitoring of medication adherence by all study participants. AiCure is the proud recipient of over $3.4 million in innovation awards from the National Institutes of Health.